Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study

IntroductionClinical remission as a multicomponent treatment goal in severe asthma is being explored in clinical practice. This post hoc analysis used data from the REDES study to assess the proportion of patients with severe eosinophilic asthma achieving our multicomponent definitions of clinical r...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	Ian Pavord, Frances Gardiner, Liam G. Heaney, Christian Domingo, Robert G. Price, Alison Pullan, John Oppenheimer, Guy Brusselle, Hiroyuki Nagase, Geoffrey Chupp, Emilio Pizzichini, David Bañas-Conejero, Peter Howarth
Fformat:	Erthygl
Iaith:	English
Cyhoeddwyd:	Frontiers Media S.A. 2023-04-01
Cyfres:	Frontiers in Immunology
Pynciau:	severe asthma remission clinical outcomes real-world eosinophil biology mepolizumab
Mynediad Ar-lein:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1150162/full

Eitemau Tebyg

A Case of Eosinophilic Gastroenteritis Remission Achieved Steroid-Free With Mepolizumab
gan: Yuki Hirata, et al.
Cyhoeddwyd: (2022-01-01)

Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study
gan: Masanobu Ueno, et al.
Cyhoeddwyd: (2022-06-01)

Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease
gan: Mkorombindo T, et al.
Cyhoeddwyd: (2019-08-01)

Evaluation of Clinical Remission in Best-Performing Severe Asthmatic Patients Treated for Three Years with Mepolizumab
gan: Diego Bagnasco, et al.
Cyhoeddwyd: (2024-04-01)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
gan: Steven W. Yancey, et al.
Cyhoeddwyd: (2019-09-01)

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
gan: Haldar P
Cyhoeddwyd: (2017-06-01)

Mepolizumab-responsive recurrent eosinophilic eruption without peripheral eosinophilia
gan: Nina B. Curkovic, MD, et al.
Cyhoeddwyd: (2024-11-01)

The clinical question of mepolizumab in the long-term treatment of idiopathic chronic eosinophilic pneumonia; how long should we use mepolizumab?
gan: Masamitsu Hamakawa, et al.
Cyhoeddwyd: (2024-01-01)

Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis
gan: Masanobu Ueno, et al.
Cyhoeddwyd: (2021-03-01)

Effectiveness of mepolizumab for eosinophilic pneumonia following bronchial thermoplasty
gan: Ryota Otoshi, et al.
Cyhoeddwyd: (2020-03-01)

Clinical efficacy of mepolizumab in the treatment of severe eosinophilic asthma in children
gan: V. N. Drozdov, et al.
Cyhoeddwyd: (2020-11-01)

Real-life efficacy and safety of mepolizumab for eosinophilic granulomatosis with polyangiitis
gan: Giuseppe A. Ramirez, et al.
Cyhoeddwyd: (2022-12-01)

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
gan: Pelaia C, et al.
Cyhoeddwyd: (2017-10-01)

May mepolizumab used in asthma correct subfertility?
gan: Guzin Ozden, et al.
Cyhoeddwyd: (2021-01-01)

Allergic bronchopulmonary aspergillosis complicated by eosinophilic chronic rhinosinusitis successfully treated with mepolizumab
gan: Nobuhiro Matsumoto, et al.
Cyhoeddwyd: (2019-10-01)

Experience with mepolizumab in adults with severe eosinophilic asthma: a case series from India
gan: Venkata Nagarjuna Maturu, et al.
Cyhoeddwyd: (2021-08-01)

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
gan: Takanori Numata, et al.
Cyhoeddwyd: (2019-10-01)

Clinical Remission Criteria and Serum Levels of Type 2 Inflammation Mediators during 24 Weeks of Treatment with the Anti-IL-5 Drug Mepolizumab in Patients with T2-High Severe Asthma
gan: Jolita Palacionyte, et al.
Cyhoeddwyd: (2024-06-01)

Mepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumab
gan: Alistair Cook, et al.
Cyhoeddwyd: (2021-05-01)

Predictors of the enhanced response to mepolizumab treatment for severe eosinophilic asthma: A retrospective, long-term study
gan: Takanori Numata, et al.
Cyhoeddwyd: (2020-01-01)

Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study
gan: Kenneth R. Chapman, et al.
Cyhoeddwyd: (2024-02-01)

Response to case report: Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy
gan: I. J. Pouliquen, et al.
Cyhoeddwyd: (2017-11-01)

Mepolizumab para el tratamiento de asma grave eosinofílica
gan: Armando Partida-Gaytán, et al.
Cyhoeddwyd: (2021-01-01)

When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report
gan: M. Sabbe, et al.
Cyhoeddwyd: (2024-01-01)

Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan
gan: Takashi Yamane, et al.
Cyhoeddwyd: (2023-06-01)

Mepolizumab Therapy for Recalcitrant Eosinophilic Annular Erythema in an Adult: A Case Report and Review of Treatment Options
gan: Magdalena Żychowska, et al.
Cyhoeddwyd: (2020-06-01)

Case Report: Mepolizumab in the treatment of idiopathic chronic eosinophilic pneumonia [version 3; peer review: 2 approved]
gan: Moetemri Zied, et al.
Cyhoeddwyd: (2023-09-01)

Real-world outcomes of mepolizumab treatment in severe eosinophilic asthma patients - retrospective cohort study in Slovakia
gan: Milos Jesenak, et al.
Cyhoeddwyd: (2023-09-01)

Idiopathic hypereosinophilic syndrome with eosinophilic cellulitis-like cutaneous involvement treated with mepolizumab and dapsone
gan: Madeleine Lachance, MD, et al.
Cyhoeddwyd: (2022-04-01)

Combination effect of Mepolizumab and Endobronchial Watanabe Spigot (EWS) in drug‐induced eosinophilic pneumonia complicated by refractory pneumothorax
gan: Nana Ayame, et al.
Cyhoeddwyd: (2024-09-01)

Switching from omalizumab to mepolizumab therapy improved extra‐pulmonary abdominal and cutaneous vasculitis symptoms in a patient with eosinophilic granulomatosis with polyangiitis
gan: Yu‐Hsuan Chen, et al.
Cyhoeddwyd: (2022-01-01)

Role of mepolizumab in severe allergic asthma with vocal cord polyp
gan: Azmat Karim, et al.
Cyhoeddwyd: (2022-01-01)

Very long-term data on patients with severe eosinophilic asthma treated with mepolizumab: a case series
gan: Carlo Lombardi, et al.
Cyhoeddwyd: (2024-07-01)

Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions
gan: Peter G. Gibson, et al.
Cyhoeddwyd: (2021-06-01)

Severe asthma remaining well‐controlled after mepolizumab discontinuation: A case report and literature review
gan: Takahiro Matsuyama, et al.
Cyhoeddwyd: (2023-06-01)

Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis
gan: Nami Masumoto, et al.
Cyhoeddwyd: (2023-05-01)

Severe eosinophilic bronchial asthma: new therapeutic options
gan: N. M. Nenasheva
Cyhoeddwyd: (2018-10-01)

Low-dose anti-IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance
gan: Marco Caminati, et al.
Cyhoeddwyd: (2023-09-01)

Gastrointestinal Involvement of Eosinophilic Granulomatosis with Polyangiitis with Histological Evidence of Treatment Response
gan: Mark Lai, et al.
Cyhoeddwyd: (2023-03-01)

Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma
gan: Manuel David Gil-Sierra, et al.
Cyhoeddwyd: (2019-11-01)